Pre-IPO TYK Medicines (PHIP Updates) - Some Points Worth the Attention
TYK has differentiated indication for core product, but it faces uncertainty in R&D. Cash shortage is an issue. We recommend a more cautious...
Pre-IPO TYK Medicines - Survival Risk Is Imminent, with Limited Highlights in the Pipeline
Except TY-9591 for brain metastases from NSCLC, the rest pipeline has little highlight but with fierce competition.As a biotech with no...
No more insights